The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.
ApexOnco Front Page
Recent articles
Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.
But the reasons for its all-stock acquisition of AcroImmune seem more prosaic.
But some phase 3 details are unconfirmed, and phase 2 data haven’t shed light on the biggest question.
BDTX-1535 takes aim at PACC mutations and Tagrisso resistance.
Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.
What similarly acting projects are still unpartnered?
After a conference lacking the wow factor, biotech winners and losers emerge.
